These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30307321)

  • 1. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future.
    Mehta P; Bothiraja C; Kadam S; Pawar A
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S791-S806. PubMed ID: 30307321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dry powder inhalable formulations for anti-tubercular therapy.
    Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
    Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
    Momin MAM; Tucker IG; Das SC
    Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dry powder inhalers of antitubercular drugs.
    Nainwal N; Sharma Y; Jakhmola V
    Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need.
    Patil TS; Deshpande AS; Deshpande S; Shende P
    J Drug Target; 2019 Jan; 27(1):12-27. PubMed ID: 29561179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs.
    Patil TS; Deshpande A; Shende PK; Deshpande S; Gaud R
    Crit Rev Ther Drug Carrier Syst; 2019; 36(3):239-276. PubMed ID: 31679248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled dry powder formulations for treating tuberculosis.
    Das S; Tucker I; Stewart P
    Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phytoconstituent based dry powder inhalers as biomedicine for the management of pulmonary diseases.
    Mehta P; Bothiraja C; Mahadik K; Kadam S; Pawar A
    Biomed Pharmacother; 2018 Dec; 108():828-837. PubMed ID: 30372894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery.
    Miranda MS; Rodrigues MT; Domingues RMA; Torrado E; Reis RL; Pedrosa J; Gomes ME
    Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():1090-1103. PubMed ID: 30274040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis.
    Dharmadhikari AS; Kabadi M; Gerety B; Hickey AJ; Fourie PB; Nardell E
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2613-9. PubMed ID: 23529740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications.
    Kumar R; Mehta P; Shankar KR; Rajora MAK; Mishra YK; Mostafavi E; Kaushik A
    Pharm Res; 2022 Nov; 39(11):2831-2855. PubMed ID: 35552983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.
    Stewart IE; Lukka PB; Liu J; Meibohm B; Gonzalez-Juarrero M; Braunstein MS; Lee RE; Hickey AJ
    Pharm Res; 2019 Jul; 36(9):136. PubMed ID: 31321552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory Tract: Structure and Attractions for Drug Delivery Using Dry Powder Inhalers.
    ElKasabgy NA; Adel IM; Elmeligy MF
    AAPS PharmSciTech; 2020 Aug; 21(7):238. PubMed ID: 32827062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active pulmonary targeting against tuberculosis (TB) via triple-encapsulation of Q203, bedaquiline and superparamagnetic iron oxides (SPIOs) in nanoparticle aggregates.
    Poh W; Ab Rahman N; Ostrovski Y; Sznitman J; Pethe K; Loo SCJ
    Drug Deliv; 2019 Dec; 26(1):1039-1048. PubMed ID: 31691600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitubercular inhaled therapy: opportunities, progress and challenges.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2005 Apr; 55(4):430-5. PubMed ID: 15761077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
    Rawal T; Kremer L; Halloum I; Butani S
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis.
    Hickey AJ; Misra A; Fourie PB
    J Pharm Sci; 2013 Nov; 102(11):3900-7. PubMed ID: 23963705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
    Rawal T; Parmar R; Tyagi RK; Butani S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.